Market Cap | 25.95M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -20.13M | Forward P/E | -1.51 | EPS next Y | - | 50D Avg Chg | 44.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -24.00% |
Dividend | N/A | Price/Book | 10.69 | EPS next 5Y | - | 52W High Chg | -84.00% |
Recommedations | 2.00 | Quick Ratio | 0.48 | Shares Outstanding | 12.14M | 52W Low Chg | 83.00% |
Insider Own | 37.61% | ROA | -172.83% | Shares Float | 12.75B | Beta | 0.95 |
Inst Own | 1.53% | ROE | - | Shares Shorted/Prior | 40.74K/29.18K | Price | 0.26 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 559,770 | Target Price | - |
Oper. Margin | - | Earnings Date | Aug 19 | Volume | 916,728 | Change | -4.04% |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.